Drugmaker will donate meds for US push to end HIV epidemic

WASHINGTON — The Health and Human Services Department announced Thursday that California-Based Gilead Sciences Inc. has agreed to donate medications that reduce the risk of HIV transmission for up to 200,000 people a year.

"Will help us achieve our goal of ending the HIV epidemic in America!" President Donald Trump said in a celebratory tweet.

The pledge may last up to 11 years, said HHS Secretary Alex Azar. Gilead will donate its Truvada prevention pill until a second-generation version becomes available.

The Trump administration has set a goal of ending the HIV epidemic in the U.S. within 10 years.

Carl Schmid of the AIDS Institute called the donation "a really significant step," saying it will make the drug available to uninsured people. It lists for more than $20,000 per patient, per year.

Gilead Sciences said in a news release that the medication donation is one of the largest ever made in the United States and is part of the company's ongoing initiatives to help ensure that everyone who can benefit from the medicine is able to access it.

HIV is the virus that causes AIDS.

Related News

US: 45,000 Islamic State fighters taken off battlefields

Aug 11, 2016

A top U.S. commander says that the military campaigns against the Islamic State group in Iraq and Syria have taken 45,000 enemy combatants off the battlefield

Families say Colorado men killed fighting ISIS shared traits

Aug 11, 2016

Two men who were reportedly killed while fighting the Islamic State group in Syria left suburban Denver neighborhoods for a warzone because of camaraderie and an unshakeable drive to right an injustice, their families said Wednesday

2 previous force complaints against academy shooting officer

Aug 11, 2016

The officer who shot and killed a 73-year-old retired librarian during a police academy class resigned from his previous department shortly after two excessive force complaints were filed against him, according to records released Thursday

The Expert Features reports on the issues and the world’s everyday news. Handled by experts in different niches, you will find different subjects and perspectives.